Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence

Abstract

Background The measurement of thrombin generation (TG) potential by the calibrated automated thrombogram (CAT) assay provides a strong contribution in identifying patients at high risk of early disease recurrence (E-DR). However, CAT assay still needs standardization and clinical validation.

Objective In this study, we aimed to validate the role of TG for E-DR prediction by means of the fully automated ST Genesia system.

Methods A prospective cohort of 522 patients from the HYPERCAN study with newly diagnosed resected high-risk breast cancer was included. Fifty-two healthy women acted as controls. Plasma samples were tested for protein C, free-protein S, and TG by ST Genesia by using the STG-ThromboScreen reagent with and without thrombomodulin (TM).

Results In the absence of TM, patients showed significantly higher peak and ETP compared with controls. In the presence of TM, significantly lower inhibition of ETP and Peak were observed in patients compared with controls. E-DR occurred in 28 patients; these patients had significantly higher peak and endogenous thrombin potential (ETP) in the absence of TM compared with disease-free patients. Multivariable analysis identified mastectomy, luminal B HER2-neg, triple negative subtypes, and ETP as independent risk factors for E-DR. These variables were combined to generate a risk assessment score, able to stratify patients in three-risk categories. The E-DR rates were 0, 4.7, and 13.5% in the low-, intermediate-, and high-risk categories (hazard ratio = 8.7; p < 0.05, low vs. high risk).

Conclusion Our data validate the ETP parameter with a fully automated standardized system and confirm its significant contribution in identifying high-risk early breast cancer at risk for E-DR during chemotherapy.

Keywords

breast cancer - disease recurrence - hypercoagulability - risk model - thrombin generation

^# A full list of the investigators of the HYPERCAN (HYPERcoagulation in CANcer) Study Group is provided in [Supplementary Material]. HYPERCAN is registered at www.clinicaltrials.gov under the identifier: NCT02622815.

^∗ These authors contributed equally as the co-last authors.

Publication History

Received: 23 September 2020

Accepted: 07 December 2020

Article published online:
10 February 2021

• References

• 1 Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res 2016; 140 (Suppl. 01) S12-S17
• 2 Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost 2019; 45 (04) 321-325
• 3 Falanga A, Russo L, Milesi V. The coagulopathy of cancer. Curr Opin Hematol 2014; 21 (05) 423-429
• 4 Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005; 31 (01) 104-110
• 5 Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018; 10 (10) E380
• 6 Remiker AS, Palumbo JS. Mechanisms coupling thrombin to metastasis and tumorigenesis. Thromb Res 2018; 164 (Suppl. 01) S29-S33
• 7 Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003; 1 (11) 673-678
• 8 Rickles FR, Falanga A. Activation of clotting factors in cancer. Cancer Treat Res 2009; 148: 31-41
• 9 Pabinger I, van Es N, Heinze G. et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 2018; 5 (07) e289-e298
• 10 Gerotziafas GT, Taher A, Abdel-Razeq H. et al; COMPASS–CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist 2017; 22 (10) 1222-1231
• 11 Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62 (02) 126-136
• 12 Giaccherini C, Marchetti M, Masci G. et al. Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica 2019
• 13 Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res 2018; 164 (Suppl. 01) S54-S61
• 14 Falanga A, Marchetti M, Massi D. et al. Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors. J Am Acad Dermatol 2016; 74 (06) 1254-1256.e4 , e4
• 15 Falanga A, Santoro A, Labianca R. et al; HYPERCAN Study Group. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thromb Res 2016; 140 (Suppl. 01) S55-S59
• 16 Marchetti M, Giaccherini C, Masci G. et al; HYPERCAN Investigators. Thrombin generation predicts early recurrence in breast cancer patients. J Thromb Haemost 2020; 18 (09) 2220-2231
• 17 Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62 (05) 699-707
• 18 De Smedt E, Hemker HC. Thrombin generation is extremely sensitive to preheating conditions. J Thromb Haemost 2011; 9 (01) 233-234
• 19 Dargaud Y, Wolberg AS, Gray E, Negrier C, Hemker HC. Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15 (08) 1704-1707
• 20 Duarte RCF, Rios DRA, Rezende SM, Jardim LL, Ferreira CN, Carvalho MDG. Standardization and evaluation of the performance of the thrombin generation test under hypo- and hypercoagulability conditions. Hematol Transfus Cell Ther 2019; 41 (03) 244-252
• 21 Dargaud Y, Luddington R, Gray E. et al. Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125 (04) 353-356
• 22 Dargaud Y, Wolberg AS, Luddington R. et al. Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study. Thromb Res 2012; 130 (06) 929-934
• 23 Spronk HM, Dielis AW, De Smedt E. et al. Assessment of thrombin generation II: validation of the calibrated automated thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100 (02) 362-364
• 24 Ljungkvist M, Strandberg K, Berntorp E. et al. Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: a Nordic study. Haemophilia 2019; 25 (02) 334-342
• 25 Calzavarini S, Brodard J, Quarroz C. et al. Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: normal values and variability. Res Pract Thromb Haemost 2019; 3 (04) 758-768
• 26 Douxfils J, Morimont L, Bouvy C. et al. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost 2019; 17 (08) 1273-1287
• 27 Siguret V, Abdoul J, Delavenne X. et al. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: modeling and assessing interindividual variability. J Thromb Haemost 2019; 17 (10) 1670-1682
• 28 Pfrepper C, Metze M, Siegemund A, Klöter T, Siegemund T, Petros S. Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system. Res Pract Thromb Haemost 2020; 4 (04) 619-627
• 29 Roullet S, Labrouche S, Freyburger G. Comparison of two thrombin generation methods, CAT and ST-genesia, in liver transplant patients. Thromb Haemost 2019; 119 (06) 899-905
• 30 Talon L, Sinegre T, Lecompte T. et al. Hypercoagulability (thrombin generation) in patients with cirrhosis is detected with ST-Genesia. J Thromb Haemost 2020; 18 (09) 2177-2190
• 31 Morrow GB, Beavis J, Harper S. et al. Coagulation status of critically ill patients with and without liver disease assessed using a novel thrombin generation analyzer. J Thromb Haemost 2020; 18 (07) 1576-1585
• 32 Zermatten MG, Fraga M, Calderara DB, Aliotta A, Moradpour D, Alberio L. Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis. JHEP Rep 2020; 2 (04) 100120
• 33 Mantovani A, Danese E, Salvagno GL. et al. Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. J Endocrinol Invest 2020
• 34 Wolff AC, Hammond ME, Hicks DG. et al; American Society of Clinical Oncology, College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014; 138 (02) 241-256
• 35 Loeffen R, Kleinegris MC, Loubele ST. et al. Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J Thromb Haemost 2012; 10 (12) 2544-2554
• 36 Colleoni M, Sun Z, Price KN. et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 2016; 34 (09) 927-935
• 37 Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013; 11 (Suppl. 01) 242-253
• 38 Nijziel MR, van Oerle R, Christella M. et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003; 120 (01) 117-122
• 39 Tinholt M, Viken MK, Dahm AE. et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer 2014; 14: 845
• 40 Chaari M, Ayadi I, Rousseau A. et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer 2014; 14: 991
• 41 Tinholt M, Sandset PM, Mowinckel MC. et al. Determinants of acquired activated protein C resistance and D-dimer in breast cancer. Thromb Res 2016; 145: 78-83
• 42 Falanga A, Schieppati F, Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin Thromb Hemost 2015; 41 (07) 756-764